Delayed Neointimalization on Drug-Eluting Stents

Vascular responses to drug eluting stents: importance of delayed healing.

Polymer-based sirolimus- (Cypher) and paclitaxel-eluting (Taxus) drug eluting stents have become the treatment of choice for patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention (PCI). Although these stents reduce rates of restenosis compared with bare metal stents (BMS), late thrombosis, a life threatening complication, has emerged as a major safety c...

Drug-eluting stents.

New Drug-Eluting Stents

The introduction of drug-eluting stents (DES) has rapidly and profoundly affected the field of interventional cardiology, and DESs are now used in a majority of intracoronary stenting procedures. As a result of the innumerable “trial-and-error” endeavors, DESs have emerged as a potential solution for solving the problem of restenosis. DESs are coated stents capable of releasing single or multip...

Drug-Eluting Stents

n the history of percutaneous coronary intervention, drug-eluting stents (DES) are recognized as revolutionary technologies with their unique ability to provide both mechanical and biological solutions simultaneously to the target lesion. While the clinical success of DES depends on these 2 properties, the ability of the operator to properly deploy the device is also of utmost importance. Altho...

Drug-eluting/biodegradable stents.